Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

IRHYTHM TECHNOLOGIES, INC.

(IRTC)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/24/2021 11/26/2021 11/29/2021 11/30/2021 12/01/2021 Date
98.5(c) 98(c) 101.76(c) 105.6(c) 109.59 Last
197 778 191 631 680 282 432 268 71 288 Volume
+1.95% -0.51% +3.84% +3.77% +3.78% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 319 M - -
Net income 2021 -105 M - -
Net cash position 2021 49,5 M - -
P/E ratio 2021 -29,4x
Yield 2021 -
Sales 2022 360 M - -
Net income 2022 -92,2 M - -
Net cash position 2022 31,3 M - -
P/E ratio 2022 -34,5x
Yield 2022 -
Capitalization 3 107 M 3 107 M -
EV / Sales 2021 9,58x
EV / Sales 2022 8,55x
Nbr of Employees 1 157
Free-Float 98,3%
More Financials
Company
iRhythm Technologies, Inc. is a digital healthcare company. It focuses on diagnosing cardiac arrhythmias by combining its wearable biosensing technology with cloud-based data analytics. It provides ambulatory electrocardiogram (ECG) monitoring for patients at risk for arrhythmias. It has created a portfolio of ambulatory cardiac monitoring services on a platform, called the Zio service. Its Zio service consists of... 
More about the company
Ratings of iRhythm Technologies, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about IRHYTHM TECHNOLOGIES, INC.
11/08Morgan Stanley Adjusts Price Target on iRhythm Technologies to $114 From $77, Maintains..
MT
11/05IRHYTHM TECHNOLOGIES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION..
AQ
11/04IRhythm Technologies Announces Third Quarter 2021 Financial Results - Form 8-K
PU
11/04IRhythm Technologies, Inc. Provides Earnings Guidance for the Fourth Quarter of 2021
CI
11/04Earnings Flash (IRTC) IRHYTHM Posts Q3 Revenue $85.4M, vs. Street Est of $83.6M
MT
11/04Earnings Flash (IRTC) IRHYTHM Posts Q3 Loss $-0.81, vs. Street Est of $-1.08
MT
11/04IRHYTHM TECHNOLOGIES, INC. : Results of Operations and Financial Condition, Amendment or W..
AQ
11/04IRhythm Technologies Announces Third Quarter 2021 Financial Results
AQ
11/04IRhythm Technologies, Inc. Reports Earnings Results for the Third Quarter and Nine Mont..
CI
11/04IRhythm Technologies, Inc. Revises Revenue Guidance for the Year of 2021
CI
11/03Health Care Stocks Closing Near Intra-Day Highs
MT
11/03IRhythm Technologies Shares Surge Following CMS 2022 Medicare Physician Fee Schedule Fi..
MT
11/03Top Premarket Gainers
MT
11/02iRhythm Technologies Comments on Centers for Medicare and Medicaid Services 2022 Medica..
GL
10/21IRHYTHM TECHNOLOGIES : to Report Third Quarter 2021 Financial Results on November 4, 2021
AQ
More news
News in other languages on IRHYTHM TECHNOLOGIES, INC.
11/04IRhythm Technologies, Inc. donne ses prévisions de résultats pour le quatrième trimestr..
11/04Earnings Flash (IRTC) IRHYTHM affiche un chiffre d'affaires de 85,4 millions de dollars..
11/04IRhythm Technologies, Inc. révise ses prévisions de revenus pour l'année 2021
11/03Les actions du secteur de la santé clôturent près de leur sommet du jour
11/03Les actions d'IRhythm Technologies bondissent à la suite de la règle finale du Medicare..
More news
Analyst Recommendations on IRHYTHM TECHNOLOGIES, INC.
More recommendations
Chart IRHYTHM TECHNOLOGIES, INC.
Duration : Period :
iRhythm Technologies, Inc. Technical Analysis Chart | IRTC | US4500561067 | MarketScreener
Technical analysis trends IRHYTHM TECHNOLOGIES, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 105,60 $
Average target price 114,80 $
Spread / Average Target 8,71%
EPS Revisions
Managers and Directors
Quentin S. Blackford President, Chief Executive Officer & Director
Douglas J. Devine Chief Financial Officer
Abhijit Y. Talwalkar Chairman
Judith Lenane Chief Clinical Officer & Executive VP-Products
Mark J. Day Executive Vice President-Research & Development
Sector and Competitors